CheckMate914

Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma

EIKCS 2022: Selecting Renal Cell Carcinoma Patients for Adjuvant Therapy

ScienceLink on X: #Nivolumab #Ipilimumab #CheckMate914 #ScienceLink CCR localizado: Nivolumab + ipilimumab no alcanzaron objetivo primario de SLE, estudio CheckMate-914 / X

Nivolumab Alone, Plus Ipilimumab Being Tested in Early-Stage, High-Risk RCC

EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse

CheckMate914

CheckMate914

Adjuvant immunotherapy does not improve DFS in renal cancer

Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions - IOS Press

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments

CheckMate914

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial